share_log

Enlivex Therapeutics Analyst Ratings

Enlivex Therapeutics Analyst Ratings

Enlivex 治療師評級
Benzinga ·  2023/08/01 18:18
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/01/2023 485.94% HC Wainwright & Co. → $15 Reiterates Buy → Buy
04/24/2023 485.94% HC Wainwright & Co. → $15 Reiterates → Buy
04/05/2023 485.94% HC Wainwright & Co. → $15 Reiterates → Buy
02/24/2023 485.94% HC Wainwright & Co. → $15 Reiterates → Buy
05/02/2022 485.94% HC Wainwright & Co. $33 → $15 Maintains Buy
01/09/2020 681.25% HC Wainwright & Co. → $20 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變動 評級變動 之前/當前的評級
08/01/2023 485.94% HC Wainwright & Co. → 15 美元 重申 購買 → 購買
2023 年 4 月 24 日 485.94% HC Wainwright & Co. → 15 美元 重申 → 購買
04/05/2023 485.94% HC Wainwright & Co. → 15 美元 重申 → 購買
02/24/2023 485.94% HC Wainwright & Co. → 15 美元 重申 → 購買
05/02/2022 485.94% HC Wainwright & Co. 33 美元 → 15 美元 維護 購買
2020 年 9 月 1 日 681.25% HC Wainwright & Co. → 20 美元 啓動覆蓋開啓 → 購買

What is the target price for Enlivex Therapeutics (ENLV)?

Enlivex Therapeutics(ENLV)的目標價格是多少?

The latest price target for Enlivex Therapeutics (NASDAQ: ENLV) was reported by HC Wainwright & Co. on August 1, 2023. The analyst firm set a price target for $15.00 expecting ENLV to rise to within 12 months (a possible 485.94% upside). 4 analyst firms have reported ratings in the last year.

HC Wainwright & Co. 於2023年8月1日公佈了Enlivex Therapeutics(納斯達克股票代碼:ENLV)的最新目標股價。這家分析公司將目標股價定爲15.00美元,預計ENLV將在12個月內升至12個月內(可能上漲485.94%)。去年有4家分析公司公佈了評級。

What is the most recent analyst rating for Enlivex Therapeutics (ENLV)?

分析師對Enlivex Therapeutics(ENLV)的最新評級是多少?

The latest analyst rating for Enlivex Therapeutics (NASDAQ: ENLV) was provided by HC Wainwright & Co., and Enlivex Therapeutics reiterated their buy rating.

Enlivex Therapeutics(納斯達克股票代碼:ENLV)的最新分析師評級由HC Wainwright & Co. 提供,Enlivex Therapeutics重申了他們的買入評級。

When is the next analyst rating going to be posted or updated for Enlivex Therapeutics (ENLV)?

Enlivex Therapeutics(ENLV)的下一個分析師評級何時公佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enlivex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enlivex Therapeutics was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.

分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Enlivex Therapeutics的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月進行一次評級,因此每家公司每年應該獲得4個評級。Enlivex Therapeutics的最新評級是在2023年8月1日提交的,因此你應該預計下一個評級將在2024年8月1日左右公佈。

Is the Analyst Rating Enlivex Therapeutics (ENLV) correct?

分析師對 Enlivex Therapeutics (ENLV) 的評級正確嗎?

While ratings are subjective and will change, the latest Enlivex Therapeutics (ENLV) rating was a reiterated with a price target of $0.00 to $15.00. The current price Enlivex Therapeutics (ENLV) is trading at is $2.56, which is within the analyst's predicted range.

儘管評級是主觀的,將會發生變化,但最新的Enlivex Therapeutics(ENLV)評級得到了重申,目標股價爲0.00美元至15.00美元。Enlivex Therapeutics(ENLV)目前的交易價格爲2.56美元,在分析師的預測區間內。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論